Do new biologics meet the unmet medical need in rheumatoid arthritis? Safety and efficacy of abatacept following B-cell depletion.
Walker
Ulrich A
UA
Courvoisier
Delphine S
DS
Dudler
Jean
J
Aeberli
Daniel
D
von Kempis
Johannes
J
Scherer
Almut
A
Finckh
Axel
A
D000069594:Abatacept; D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001402:B-Lymphocytes / Q000187:drug effects*; D001688:Biological Products / Q000009:adverse effects*; D005260:Female; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D013557:Switzerland
D018501:Antirheumatic Agents; D001688:Biological Products; D018796:Immunoconjugates; D000069594:Abatacept